$EMED
Electromedical Technologies, Inc Stock $emed

$emed Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000141057822003233 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$423.2K	$279.6K	$301.2K
YoY Change	78.69%	-7.17%	46.3%
Cost Of Revenue	$90.22K	$58.01K	$66.73K
YoY Change	119.14%	-13.07%	16.29%
Gross Profit	$332.9K	$221.5K	$234.4K
YoY Change	70.17%	-5.49%	57.9%
Gross Profit Margin	78.68%	79.25%	77.84%
Selling, General & Admin	$584.8K	$558.9K	$455.0K
YoY Change	-65.2%	22.84%	-79.72%
% of Gross Profit	175.65%	252.28%	194.09%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$5.470K	$5.469K	$5.468K
YoY Change	0.0%	0.02%	0.0%
% of Gross Profit	1.64%	2.47%	2.33%
Operating Expenses	$590.3K	$558.9K	$455.0K
YoY Change	-64.99%	22.84%	-79.72%
Operating Profit	-$257.3K	-$337.4K	-$220.6K
YoY Change	-82.74%	52.95%	-89.47%
Interest Expense	-$280.7K	$160.6K	$1.105M
YoY Change	-20.93%	-85.47%	1998.58%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$620.6K	-$3.079M
YoY Change		-79.85%	4001.65%
Pretax Income	-$830.1K	-$958.0K	-$3.300M
YoY Change	-55.02%	-70.97%	52.07%
Income Tax
% Of Pretax Income
Net Earnings	-$854.8K	-$957.9K	-$3.300M
YoY Change	-53.68%	-70.97%	52.07%
Net Earnings / Revenue	-202.01%	-342.67%	-1095.71%
Basic Earnings Per Share		-$0.01	-$0.06
Diluted Earnings Per Share	$0.00	-$0.01	-$60.71K
COMMON SHARES
Basic Shares Outstanding	172.9M	149.2M	54.36M
Diluted Shares Outstanding		147.0M	54.36M

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$368.4K	$458.9K	$164.8K
YoY Change	-3.85%	178.45%	92.81%
Cash & Equivalents	$368.4K	$458.9K	$164.8K
Short-Term Investments
Other Short-Term Assets	$207.9K	$101.2K	$23.94K
YoY Change	447.03%	322.68%	-88.59%
Inventory	$62.06K	$117.6K	$229.9K
Prepaid Expenses
Receivables	$9.444K	$16.68K	$30.93K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$647.8K	$694.3K	$449.6K
YoY Change	-4.0%	54.44%	20.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$705.5K	$710.9K	$732.8K
YoY Change	-3.01%	-2.99%	-2.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$13.60K
YoY Change			-84.11%
Total Long-Term Assets	$705.5K	$710.9K	$746.4K
YoY Change	-3.01%	-4.75%	-11.17%
TOTAL ASSETS
Total Short-Term Assets	$647.8K	$694.3K	$449.6K
Total Long-Term Assets	$705.5K	$710.9K	$746.4K
Total Assets	$1.353M	$1.405M	$1.196M
YoY Change	-3.48%	17.5%	-1.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$266.7K	$277.1K	$244.3K
YoY Change	24.19%	13.44%	-26.14%
Accrued Expenses	$193.8K	$717.6K	$195.8K
YoY Change	-38.86%	266.59%	-22.94%
Deferred Revenue	$217.6K	$25.84K	$2.267K
YoY Change		1039.83%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$1.337M	$1.415M	$1.075M
YoY Change	48.68%	31.64%	120.01%
Total Short-Term Liabilities	$2.924M	$2.479M	$2.336M
YoY Change	102.76%	6.14%	70.22%
LONG-TERM LIABILITIES
Long-Term Debt	$639.7K	$651.0K	$680.9K
YoY Change	-4.99%	-4.4%	-3.85%
Other Long-Term Liabilities	$10.23K	$11.05K	$10.16K
YoY Change	11.64%	8.69%	-45.92%
Total Long-Term Liabilities	$10.23K	$11.05K	$10.16K
YoY Change	11.64%	8.69%	-98.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.924M	$2.479M	$2.336M
Total Long-Term Liabilities	$10.23K	$11.05K	$10.16K
Total Liabilities	$3.574M	$3.141M	$3.027M
YoY Change	68.22%	3.78%	44.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.83M	-$23.97M	-$20.02M
YoY Change	13.45%	19.76%
Common Stock	$1.896K	$1.577K	$747.00
YoY Change	116.44%	111.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.221M	-$1.736M	-$1.831M
YoY Change
Total Liabilities & Shareholders Equity	$1.353M	$1.405M	$1.196M
YoY Change	-3.48%	17.5%	-1.56%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$854.8K	-$957.9K	-$3.300M
YoY Change	-53.68%	-70.97%	52.07%
Depreciation, Depletion And Amortization	$5.470K	$5.469K	$5.468K
YoY Change	0.0%	0.02%	0.0%
Cash From Operating Activities	-$33.10K	-$324.5K	-$177.6K
YoY Change	-88.49%	82.74%	-67.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-57.39K	718.2K	-38.07K
YoY Change	-111.34%	-1986.42%	-107.49%
NET CHANGE
Cash From Operating Activities	-33.10K	-324.5K	-177.6K
Cash From Investing Activities
Cash From Financing Activities	-57.39K	718.2K	-38.07K
Net Change In Cash	-90.49K	393.7K	-215.6K
YoY Change	-141.44%	-282.58%	418.34%
FREE CASH FLOW
Cash From Operating Activities	-$33.10K	-$324.5K	-$177.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	146993139
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54356854
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119799025
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39670934
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	172884530
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	458915
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	383170
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	dei	Entity Registrant Name EntityRegistrantName	Electromedical Technologies, Inc
	dei	Entity Central Index Key EntityCentralIndexKey	0001715819
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	elcq	Debt Instrument Debt Default Extension Of Maturity Term DebtInstrumentDebtDefaultExtensionOfMaturityTerm	P5Y
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56192
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2619815
	dei	Entity Address Address Line1 EntityAddressAddressLine1	16561 N. 92nd Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ste. 101
	dei	Entity Address City Or Town EntityAddressCityOrTown	Scottsdale
	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85260
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	880-7888
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16681
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35085
CY2022Q3	us-gaap	Inventory Net InventoryNet	117550
CY2021Q4	us-gaap	Inventory Net InventoryNet	218510
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	101194
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38002
CY2022Q3	us-gaap	Assets Current AssetsCurrent	694340
CY2021Q4	us-gaap	Assets Current AssetsCurrent	674767
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	710938
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	727344
CY2022Q3	us-gaap	Assets Assets	1405278
CY2021Q4	us-gaap	Assets Assets	1402111
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	277085
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	214785
CY2022Q3	elcq	Credit Cards Payable CreditCardsPayable	43031
CY2021Q4	elcq	Credit Cards Payable CreditCardsPayable	11283
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	717628
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	317037
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25840
CY2022Q3	elcq	Discount On Convertible Promissory Notes Current DiscountOnConvertiblePromissoryNotesCurrent	592869
CY2021Q4	elcq	Discount On Convertible Promissory Notes Current DiscountOnConvertiblePromissoryNotesCurrent	723166
CY2022Q3	elcq	Convertible Promissory Notes Payable Current ConvertiblePromissoryNotesPayableCurrent	1384327
CY2021Q4	elcq	Convertible Promissory Notes Payable Current ConvertiblePromissoryNotesPayableCurrent	811687
CY2022Q3	elcq	Related Party Notes Payable Current RelatedPartyNotesPayableCurrent	0
CY2021Q4	elcq	Related Party Notes Payable Current RelatedPartyNotesPayableCurrent	57875
CY2022Q3	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	31119
CY2021Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	29502
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2479030
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1442169
CY2022Q3	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	497079
CY2021Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	518849
CY2022Q3	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	153882
CY2021Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	154429
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11045
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9167
CY2022Q3	us-gaap	Liabilities Liabilities	3141036
CY2021Q4	us-gaap	Liabilities Liabilities	2124614
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	999000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	157950530
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87725842
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	1577
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	876
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	21867892
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20804333
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23970227
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21882712
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1735758
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-722503
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1405278
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1402111
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	279551
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	301157
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	726696
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	670551
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	58008
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	66733
	us-gaap	Cost Of Revenue CostOfRevenue	170984
	us-gaap	Cost Of Revenue CostOfRevenue	158065
CY2022Q3	us-gaap	Gross Profit GrossProfit	221543
CY2021Q3	us-gaap	Gross Profit GrossProfit	234424
	us-gaap	Gross Profit GrossProfit	555712
	us-gaap	Gross Profit GrossProfit	512486
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	558919
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	454997
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1901908
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2822251
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-337376
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-220573
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1346196
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2309765
CY2022Q3	us-gaap	Interest Expense InterestExpense	160570
CY2021Q3	us-gaap	Interest Expense InterestExpense	1105069
	us-gaap	Interest Expense InterestExpense	510417
	us-gaap	Interest Expense InterestExpense	2937851
CY2021Q3	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1974164
	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1436756
	elcq	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	-432
	elcq	Debt Instrument Forgiveness Of Debt DebtInstrumentForgivenessOfDebt	-50082
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-460000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-781800
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-620570
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3079233
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1292217
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4324957
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-957946
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3299806
	us-gaap	Net Income Loss NetIncomeLoss	-2638413
	us-gaap	Net Income Loss NetIncomeLoss	-6634722
CY2022Q3	elcq	Deemed Dividend Related To Warrant Resets DeemedDividendRelatedToWarrantResets	19780
CY2021Q3	elcq	Deemed Dividend Related To Warrant Resets DeemedDividendRelatedToWarrantResets	8396
	elcq	Deemed Dividend Related To Warrant Resets DeemedDividendRelatedToWarrantResets	83161
	elcq	Deemed Dividend Related To Warrant Resets DeemedDividendRelatedToWarrantResets	3748695
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-977726
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3308202
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2721574
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10383417
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146993139
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54356854
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119799025
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39670934
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-722503
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	356900
CY2022Q1	elcq	Adjustments To Additional Paid In Capital Warrants Issued In Conjunction With Convertible Promissory Notes AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConjunctionWithConvertiblePromissoryNotes	142996
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42766
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4703
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1144536
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1699029
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	45000
CY2022Q2	elcq	Stock Issued During Period Value In Conjunction Forbearance Of Convertible Debt StockIssuedDuringPeriodValueInConjunctionForbearanceOfConvertibleDebt	142800
CY2022Q2	elcq	Stock Issued During Period Value In Conjunction With Convertible Promissory Notes StockIssuedDuringPeriodValueInConjunctionWithConvertiblePromissoryNotes	668370
CY2022Q2	elcq	Warrants Issued In Conjunction With Debt Extinguishment WarrantsIssuedInConjunctionWithDebtExtinguishment	65000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-535931
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-1313790
CY2022Q3	elcq	Adjustments To Additional Paid In Capital Warrants Issued In Conjunction With Convertible Promissory Notes AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConjunctionWithConvertiblePromissoryNotes	302978
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	155000
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	68000
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-957946
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1735758
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1318603
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	693826
CY2021Q1	elcq	Adjustments To Additional Paid In Capital Warrants Issued In Conjunction With Convertible Promissory Notes AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConjunctionWithConvertiblePromissoryNotes	420096
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	380103
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	604901
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2560384
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-1780061
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	974314
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	110400
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-774532
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1469879
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2939077
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3299806
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1830608
	us-gaap	Profit Loss ProfitLoss	-2638413
	us-gaap	Profit Loss ProfitLoss	-6634722
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3495
	us-gaap	Share Based Compensation ShareBasedCompensation	484603
	us-gaap	Share Based Compensation ShareBasedCompensation	1409127
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16406
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16406
	elcq	Forgiveness Of Debt Instrument ForgivenessOfDebtInstrument	49783
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-781800
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	367257
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2785844
	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1436756
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-2839
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-18404
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16732
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-100960
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	151194
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	63192
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-261924
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-7000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	62300
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11350
	elcq	Increase Decrease In Credit Card Payables IncreaseDecreaseInCreditCardPayables	31748
	elcq	Increase Decrease In Credit Card Payables IncreaseDecreaseInCreditCardPayables	-8941
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	70171
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	75083
	elcq	Increase Decrease In Customer Deposits Operating Activities IncreaseDecreaseInCustomerDepositsOperatingActivities	25840
	elcq	Increase Decrease In Customer Deposits Operating Activities IncreaseDecreaseInCustomerDepositsOperatingActivities	-26384
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1878
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-5441
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-99000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1545140
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	937500
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	693348
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-740238
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-906073
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	20700
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	19684
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-57875
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12846
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42766
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	815983
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	805970
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	75745
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-100103
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	383170
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264913
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	458915
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	164810
	us-gaap	Interest Paid Net InterestPaidNet	89079
	us-gaap	Interest Paid Net InterestPaidNet	29625
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
	elcq	Adoption Of Accounting Standard AdoptionOfAccountingStandard	379355
	elcq	Warrants Common Stock And Beneficial Conversion Feature Issued In Conjunction With Convertible Promissory Note WarrantsCommonStockAndBeneficialConversionFeatureIssuedInConjunctionWithConvertiblePromissoryNote	653774
	elcq	Warrants Common Stock And Beneficial Conversion Feature Issued In Conjunction With Convertible Promissory Note WarrantsCommonStockAndBeneficialConversionFeatureIssuedInConjunctionWithConvertiblePromissoryNote	420096
	elcq	Derivative Liabilities Issued In Conjunction With Convertible Promissory Notes DerivativeLiabilitiesIssuedInConjunctionWithConvertiblePromissoryNotes	1197607
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	823370
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4290655
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of certain assets and liabilities, certain disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates affecting the financial statements have been prepared on the basis of the most current and best available information. However, actual results from the resolution of such estimates and assumptions may vary from those used in the preparation of the financial statements.</p>
	elcq	Accumulated Net Loss AccumulatedNetLoss	20200000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-740238
	elcq	Working Capital Deficit WorkingCapitalDeficit	1784690
	elcq	Right Of Return Period RightOfReturnPeriod	P30D
	elcq	Sales Returns Allowance SalesReturnsAllowance	6990
CY2021	elcq	Sales Returns Allowance SalesReturnsAllowance	6990
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25840
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
	elcq	Initial Warranty Period InitialWarrantyPeriod	P3Y
CY2022Q3	us-gaap	Deferred Income DeferredIncome	26408
CY2021Q4	us-gaap	Deferred Income DeferredIncome	28252
CY2022Q3	us-gaap	Receivables From Customers ReceivablesFromCustomers	13718
CY2021Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	13300
CY2022Q3	us-gaap	Due From Customer Acceptances DueFromCustomerAcceptances	0
CY2021Q4	us-gaap	Due From Customer Acceptances DueFromCustomerAcceptances	4575
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25840
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
CY2022Q3	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	61000
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	61000
	elcq	Standard Warranty Period StandardWarrantyPeriod	P3Y
CY2022Q3	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	13109
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	14828
	elcq	Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Outstanding Warrants Stock Options And Convertible Promissory Notes IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfOutstandingWarrantsStockOptionsAndConvertiblePromissoryNotes	170000000.0
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	899987
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	899987
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	189049
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	172643
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	710938
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	727344
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5469
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5469
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16406
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16406
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	158875
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	57875
CY2022Q3	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	0
CY2021Q3	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	7561
	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	78
	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	14182
CY2022Q2	elcq	Number Of Warrants Issued NumberOfWarrantsIssued	2500000
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.025
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1977196
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1534853
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	592869
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	21000000
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.025
CY2022Q2	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	500000
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	2500000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	723166
CY2022Q3	us-gaap	Notes Payable NotesPayable	1384327
CY2021Q4	us-gaap	Notes Payable NotesPayable	811687
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1977196
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	592869
CY2022Q3	us-gaap	Notes Payable NotesPayable	1384327
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1534853
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	723166
CY2021Q4	us-gaap	Notes Payable NotesPayable	811687
CY2021Q3	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	99000
	elcq	Number Of Warrants Exercised NumberOfWarrantsExercised	14249999
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.025
	elcq	Number Of Shares Issued Upon Exercise Of Warrants NumberOfSharesIssuedUponExerciseOfWarrants	11389887
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	50000000
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4703
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4703
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.025
CY2022Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q2	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	65000
CY2022Q2	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	259000
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	30500190
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	18468499
	elcq	Reduction To Retained Earnings And Increase In Additional Paid In Capital ReductionToRetainedEarningsAndIncreaseInAdditionalPaidInCapital	83161
	elcq	Commitment For Product Development CommitmentForProductDevelopment	525000
	elcq	Amount For Commitment For Product Development Paid AmountForCommitmentForProductDevelopmentPaid	170000

Files In Submission

Name	View Source	Status
elcq-20220930_lab.xml	Edgar Link	unprocessable
0001410578-22-003233-index-headers.html	Edgar Link	pending
0001410578-22-003233-index.html	Edgar Link	pending
0001410578-22-003233.txt	Edgar Link	pending
0001410578-22-003233-xbrl.zip	Edgar Link	pending
elcq-20220930.xsd	Edgar Link	pending
elcq-20220930x10q.htm	Edgar Link	pending
elcq-20220930x10q001.jpg	Edgar Link	pending
elcq-20220930xex10d63.htm	Edgar Link	pending
elcq-20220930xex31d1.htm	Edgar Link	pending
elcq-20220930xex32d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
elcq-20220930_cal.xml	Edgar Link	unprocessable
elcq-20220930_def.xml	Edgar Link	unprocessable
elcq-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
elcq-20220930x10q_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EMED
Electromedical Technologies, Inc Stock $emed

2022 Q4 Form 10-Q Financial Statement

#000141057822003233 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMED Electromedical Technologies, Inc Stock $emed

2022 Q4 Form 10-Q Financial Statement

#000141057822003233 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMED
Electromedical Technologies, Inc Stock $emed